Tarsus shares fall after short seller report

Tarsus Pharmaceuticals stock was down ~8% midday after Culper Research disclosed a short position and alleged XDEMVY Medicare patient copay arrangements may violate the Anti-Kickback Statute. The short seller points to large Healthwell-related charitable donations growing from $5.7M (2023) to $31.2M (2024) and $78.5M (2025), and argues Tarsus’s $25M addressable market estimate overstates eligible patients (survey: 18% vs Titan: 58% collarettes). Culper projects XDEMVY revenue could peak below $800M by 2028, well under Tarsus’s >$2B sales path.

Analysis

The market is not pricing a simple reputational hit; it is repricing the probability that TARS is a one-product story with a fragile reimbursement engine. If Medicare access is meaningfully subsidized, then the near-term risk is not a binary DOJ outcome but a slower commercial air pocket: specialty pharmacies get cautious, prescribers pause, and gross-to-net expands as the company has to defend volume. That matters more than the headline because single-asset companies trade on duration of growth, and any doubt about the true patient funnel can compress the multiple before it shows up in revenue.

The second-order effect is that the valuation debate shifts from TAM to collectability. A conservative external buyer of royalty cash flows is a useful anchor: if private capital is underwriting a much lower peak than management, the equity now has to prove not just adoption, but durable, auditable adoption after any foundation scrutiny. Over the next 1-3 months, the key catalysts are legal counsel responses, payer audits, and whether prescription momentum decelerates in Medicare-heavy channels; over 6-18 months, the real question is whether XDEMVY is a niche product with a capped runway rather than a platform.

The contrarian view is that this could be over-discounting a compliance gray area if the foundation is legally independent and the Medicare mix is actually modest. That said, the setup favors downside asymmetry because the short thesis attacks both growth and quality of earnings, and short interest can amplify any later evidence of fund dependence or channel stuffing. TEVA and Jazz are more useful as litigation analogs than direct comps: once the market believes enforcement risk is real, settlements become a duration problem, not a one-off fine.

Key Decisions for Investors

• Short TARS on any post-gap bounce over the next 1-5 trading days; target a 1-3 month catalyst window. Thesis fails if the company produces a strong third-party legal opinion plus clean Medicare mix disclosure and prescriptions re-accelerate.
• Buy TARS put spreads 1-3 months out to define risk while retaining convexity to a DOJ/CMS inquiry or payer pullback. Prefer strikes that monetize a re-rating to a lower peak-sales multiple rather than a full bankruptcy scenario.
• Pair trade: short TARS versus long XBI for a 1-3 month horizon. This isolates the idiosyncratic compliance overhang; the pair works if TARS underperforms the biotech basket on slower script growth or margin compression.
• No direct trade in BX, JAZZ, META, or TEVA from this headline alone; use BX only as a valuation read-through on royalty-market conservatism, not as a standalone catalyst.
• Set an alert for any disclosure of Medicare patient mix, Healthwell governance, or SG&A language reversal in the next filing. If those disclosures are absent or incomplete, maintain the bearish view; if they are unusually specific and verifiable, reduce short exposure quickly.